Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AC Immune Links with Piramal Imaging To Advance Alzheimer’s Research

This article was originally published in The Pink Sheet Daily

Executive Summary

Selecting the right patients for clinical trials of potential Alzheimer’s disease therapies could be easier if an agreement on the development of a PET-based diagnostic between the companies bears fruit.

You may also be interested in...

Piramal Imaging Adds New AD Tracers For Leadership In Neuroimaging Research

Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.

AC Immune Seeks Partner For First Anti-Tau Vaccine To Reach The Clinic

The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.

India’s Piramal Buys Bayer’s Molecular Imaging Research Portfolio To Bulk Up Innovative Pipeline

Piramal steadily carving out a pipeline that will give it a niche in the global pharma business.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts